Economic information and modeling reportBudget impact modelResults
Base case
6 evidence topics · 6 sources
Budget impact model of cretostimogene grenadenorepvec: base-case results
No evidence found.
Base-case budget impact of nadofaragene firadenovec in a plan of one million members
Potential budget impact of nadofaragene firadenovec in the ICER review
Base-case cost-effectiveness of radical cystectomy and bladder-sparing treatments over 5 years
Base-case cost per responder of TAR-200 versus FDA-approved comparators
Base-case incremental cost-effectiveness ratios in the ICER review, CIS ± Ta/T1
| Intervention | Cost per QALY gained | Cost per evLYG | Cost per year in progression-free state |
|---|---|---|---|
| Nadofaragene firadenovec | “$151,000”View highlighted excerpt for this quote | “$135,000”View highlighted excerpt for this quote | “$100,000”View highlighted excerpt for this quote |
| Oportuzumab monatox | “$382,000”View highlighted excerpt for this quote | “$343,000”View highlighted excerpt for this quote | “$281,000”View highlighted excerpt for this quote |
| Pembrolizumab | “$114,000”View highlighted excerpt for this quote | “$103,000”View highlighted excerpt for this quote | “$76,000”View highlighted excerpt for this quote |